Literature DB >> 4263497

Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.

S V Pizzo, M L Schwartz, R L Hill, P A McKee.   

Abstract

Fibrin formed in response to ancrod, reptilase, or thrombin was reduced by beta-mercaptoethanol and examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. It was found that ancrod progressively and totally digested the alpha-chains of fibrin monomers at sites different than plasmin; however, further digestion of fibrin monomers by either reptilase or thrombin was not observed. Highly purified ancrod did not activate fibrin-stabilizing factor (FSF); however, the reptilase preparation used in these experiments, like thrombin, activated FSF and thereby promoted cross-link formation. Fibrin, formed by clotting purified human fibrinogen with ancrod, reptilase, or thrombin for increasing periods of time in the presence of plasminogen, was incubated with urokinase and observed for complete lysis. Fibrin formed by ancrod was strikingly more vulnerable to plasmin digestion than was fibrin formed by reptilase or thrombin. The lysis times for fibrin formed for 2 hr by ancrod, reptilase, or thrombin were 18, 89, and 120 min, respectively. Evidence was also obtained that neither ancrod nor reptilase activated human plasminogen. These results indicate that fibrin formed by ancrod is not cross-linked and has significantly degraded alpha-chains: as expected, ancrod-formed fibrin is markedly susceptible to digestion by plasmin.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4263497      PMCID: PMC292433          DOI: 10.1172/JCI107107

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Experimental production of microangiopathic haemolytic anaemia in vivo.

Authors:  M L Rubenberg; B S Bull; E Regoeczi; J V Dacie; M C Brain
Journal:  Lancet       Date:  1967-11-25       Impact factor: 79.321

2.  Anticoagulant therapy with a purified fraction of Malayan pit viper venom.

Authors:  A A Sharp; B A Warren; A M Paxton; M J Allington
Journal:  Lancet       Date:  1968-03-09       Impact factor: 79.321

3.  Pharmacology and toxicology of a defibrinating substance from Malayan pit viper venom.

Authors:  A Ashford; J W Ross; P Southgate
Journal:  Lancet       Date:  1968-03-09       Impact factor: 79.321

4.  The paradox in therapeutic defibrination.

Authors:  H A Reid; K E Chan
Journal:  Lancet       Date:  1968-03-09       Impact factor: 79.321

5.  Therapeutic defibrination in the treatment of thrombotic disease.

Authors:  W R Bell; W R Pitney; J F Goodwin
Journal:  Lancet       Date:  1968-03-09       Impact factor: 79.321

6.  The effect of arvin on blood coagulation factors.

Authors:  W R Bell; G Bolton; W R Pitney
Journal:  Br J Haematol       Date:  1968-12       Impact factor: 6.998

7.  A study of the coagulant properties of Malayan pit-viper venom.

Authors:  K E Chan; C R Rizza; M P Henderson
Journal:  Br J Haematol       Date:  1965-11       Impact factor: 6.998

8.  The role of the reticuloendothelial system in diffuse, low grade intravascular coagulation.

Authors:  L Lee; P H Prose; M H Cohen
Journal:  Thromb Diath Haemorrh Suppl       Date:  1966

9.  The isolation and properties of the thrombin-like activity from Ancistrodon rhodostoma venom.

Authors:  M P Esnouf; G W Tunnah
Journal:  Br J Haematol       Date:  1967-07       Impact factor: 6.998

10.  In vivo effects of Agkistrodon rhodostoma venom: studies with fibrinogen-131I.

Authors:  E Regoeczi; J Gergely; A S McFarlane
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

View more
  9 in total

1.  In vivo defibrination results in markedly decreased amounts of fibrinogen in rat megakaryocytes and platelets.

Authors:  P J Handagama; M A Shuman; D F Bainton
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  Fibrin assembly after fibrinopeptide A release in model systems and human plasma studied with magnetic birefringence.

Authors:  J Torbet
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

3.  Postsurgical hemorrhage in dogs anticoagulated with ancrod (Arvin).

Authors:  C L Slade; L M Taylor; A S Wechsler; P A McKee
Journal:  Ann Surg       Date:  1973-12       Impact factor: 12.969

4.  Ancrod and fibrin formation: perspectives on mechanisms of action.

Authors:  Shuo Liu; Victor J Marder; David E Levy; Shur-Jen Wang; Fan Yang; Annlia Paganini-Hill; Mark J Fisher
Journal:  Stroke       Date:  2011-08-25       Impact factor: 7.914

5.  Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog.

Authors:  T M Daniel; S V Pizzo; P A Mckee
Journal:  Ann Surg       Date:  1976-08       Impact factor: 12.969

6.  Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice.

Authors:  Bihui Huang; Arun B Deora; Kai-Li He; Kang Chen; Guangzhi Sui; Andrew T Jacovina; Dena Almeida; Peng Hong; Paul Burgman; Katherine A Hajjar
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

Review 7.  Antithrombotic drugs: part II.

Authors:  A S Gallus; J Hirsh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 8.  Defibrinogenating enzymes.

Authors:  W R Bell
Journal:  Drugs       Date:  1997       Impact factor: 9.546

9.  Purification, Characterization and Evaluation of the Antitumoral Activity of a Phospholipase A2 from the Snake Bothrops moojeni.

Authors:  Breno Emanuel Farias Frihling; Ana Paula de Araújo Boleti; Caio Fernando Ramalho de Oliveira; Simone Camargo Sanches; Pedro Henrique de Oliveira Cardoso; Newton Verbisck; Maria Lígia Rodrigues Macedo; Paula Helena Santa Rita; Cristiano Marcelo Espinola Carvalho; Ludovico Migliolo
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.